SULT1A1 (Minoxidil Sulfotransferase) Enzyme Booster Significantly Improves Response to Topical Minoxidil for Hair Regrowth

waynakyo

Experienced Member
Reaction score
466
Is this something people are experimenting with on here?

Abstract​

Background: Minoxidil is a widely used over the counter topical treatment for hair loss. The response rate for topical minoxidil is relatively low. Minoxidil is a pro-drug, converted to its active form, minoxidil sulfate, by SULT1A1 enzymes located in the scalp. Recently, a novel topical formula that increases the activity of SULT1A1 in hair follicles was reported.
Aims: To evaluate any benefit of applying the SULT1A1 enzyme booster prior to daily 5% minoxidil treatment.
Methods: Male androgenic alopecia patients were recruited to a randomized blinded placebo controlled study. Patients were randomized to receive 5% topical minoxidil plus the novel formula or minoxidil plus a sham adjuvant. Patient's hair growth was monitored using global photography over 60 days.
Results: Twenty-four males with androgenic alopecia (Norwood scale average 4.4, range 2-6) were randomized and completed the trial; 12 in the active arm and 12 in placebo. 75% of the subjects who used the SULT1A1 adjuvant with their daily minoxidil treatments for 60 days regrew hair verses 33% of those using the placebo adjuvant (p=0.023).
Conclusions: In a small cohort of androgenetic alopecia men, adding the SULT1A1 adjuvant to their daily minoxidil treatment regimen improved hair regrowth.

 

xaragedom

Established Member
My Regimen
Reaction score
65
But what are the ingredients of this formula? Does anybody have access to full paper?
 

Jakejr

Experienced Member
My Regimen
Reaction score
335
SULT1A1 seems is an expensive exotic substance… 33% improvement? We need much more than that…
Methinks another wild goose chase..
 

Kev123

Experienced Member
My Regimen
Reaction score
387
lol tretinoin already boosts the enzyme


“Results: After therapy, increases in the macrophotographic variables of total hair count and non-vellus hair count were shown in both treatment groups. There were no statistically significant differences between the two treatment groups with respect to changes in macrophotographic variables or scores on subjective global assessments by patients and the investigator. The incidence of adverse effects such as pruritus or local irritation was similar in the 5% minoxidil group (4 of 14 subjects) and the combined agent group (5 of 15 subjects).

Conclusion: The efficacy and safety of combined 5% minoxidil and 0.01% tretinoin once-daily therapy appear to be equivalent to those of conventional 5% minoxidil twice-daily therapy for the treatment of Androgenetic Alopecia.”

 
Top